Having previously updated the risks specified on the product monograph for one type of Janus Kinase inhibitor, Health Canada now says it can't rule out similar risks for other types.
The organization's annual report for 2021, Navigating a World in Transition, covers the key moves for last year, as well as what's coming up in the rest of 2022.